Universal Health Coverage: what it means for viral hepatitis

– written by Cary James, World Hepatitis Alliance CEO

On Monday 23rd September I attended the United Nations (UN) High Level Meeting on Universal Health Coverage (UHC) in New York to represent WHA members.

It was heartening to hear hepatitis mentioned in addresses from the President of Georgia and the Prime Minister of Bhutan at this prestigious event. I was also delighted to see that Prime Minister of Bangladesh, Sheikh Hasina, has been awarded the Global Alliance for Vaccination and Immunisations (GAVI) Vaccine Hero award in recognition of Bangladesh’s outstanding success in vaccinating children against diseases, including hepatitis B.

These recent events indicate that hepatitis elimination is becoming more of a priority in countries around the world. It is thanks to the tireless work of WHA members and the global hepatitis community that hepatitis is increasingly prominent on the world stage. We now need to ensure that this is translated to the country level.

Recently, WHA advocated successfully for hepatitis to be included in the Political Declaration on UHC which was signed by world leaders at the High Level Meeting on Monday 23 September. This is the start of an increasing focus on UHC in the coming months and years, and it is vital that we keep hepatitis high on the UHC agenda.

To help you understand UHC, how it relates to hepatitis, and what you can do to help ensure this new commitment to hepatitis elimination is turned into action, we have put together a short briefing on UHC. I also hosted a live broadcast on UHC and hepatitis which you can catch up on here.

Cary James, CEO

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close